Table 1.

Patients Who Underwent Liver Transplantation From January 1, 2002–to March 31, 2018, in the US.

		Total population		Pre-DAA		Post-DAA
		N	%	N	%	n	%
Sex	Male	64,757	66.66%	45,438	66.97%	19,319	65.93%
	Female	32,390	33.34%	22,407	33.03%	9983	34.07%
				χ2	9.9618	P	0.002
Ethnicity	White	69,734	72.59%	48,911	72.82%	20,823	72.05%
	Black	9144	9.52%	6441	9.59%	2703	9.35%
	Hispanic	12,840	13.37%	8716	12.98%	4124	14.27%
	Asian	4346	4.52%	3095	4.61%	1251	4.33%
				χ2	31.597	P	<0.001
HCV	No	67,834	69.84%	46,066	67.91%	21,768	74.30%
	Yes	29,295	30.16%	21,765	32.09%	7530	25.70%
				χ2	395.78	P	<0.001
HCC	No	78,260	80.57%	56,125	72.06%	22,135	74.62%
	Yes	18,869	19.43%	21,765	27.94%	7530	25.38%
				χ2	675.51	P	<0.001
Diabetes	No	71,382	74.56%	50,543	76.00%	20,839	71.28%
	Yes	24,355	25.44%	15,957	24.00%	8398	28.72%
				χ2	239.13	P	<0.001
Era	Pre-DAA	66,174	68.12%
	Post-DAA	30,973	31.88%
		Mean		Mean		Mean
Age at listing		53.34		52.95	<0.001	54.95
				t-test
BMI at transplant		28.6		28.42	<0.001	29.01
				t-test
Biological MELD at transplant		22.07		21.71	<0.001	23.09
				t-test
		Overall		Era 1		Era 2
Graft failure	No	66,174	68.12%	40,557	71.76%	25,617	75.31%
	Yes	30,973	31.88%	15,957	28.24%	8398	24.69%
				χ2	7200	P	<0.001
Patient status	Died	26,332	27.11%	23,268	34.31%	3044	10.39%
	Retransplanted	4559	4.69%	3926	5.79%	633	2.16%
	Alive at last known follow-up	66,256	68.20%	40,631	59.91%	25625	87.45%
				χ2	7178.9	P	<0.001

DAA = direct-acting antiviral; HCV = hepatitis C virus; HCC = hepatocellular carcinoma; BMI = body mass index.